NEWS Webinar – The Role of Nimotuzumab in the Treatment of Head and Neck and Nasopharyngeal Cancer ByOncoscience 28. May 20224. March 2025
Allgemein | NEWS Specific Pharma A/S and Oncoscience GmbH launch a Named Patient Program for the treatment of cancer with nimotuzumab. ByOncoscience 6. November 20204. March 2025
Allgemein Children with diffuse intrinsic pons glioma (DIPG) benefit from nimotuzumab ByOncoscience 25. March 20194. March 2025
NEWS Mawdsleys and Oncoscience launch a Named Patient Program for CIMAher® (Nimotuzumab) in the U.K. and Ireland ByOncoscience 3. October 20184. March 2025
NEWS Publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab in combination with gemcitabine. ByOncoscience 17. November 20174. March 2025
NEWS Oncoscience AG attends the Nimotuzumab Global Scientific Meeting, 7th-10th April 2016 in Varadero/ Cuba ByOncoscience 7. April 2016
NEWS Innokeys Pte. Ltd Consolidates Nimotuzumab Development by Acquiring Oncoscience AG ByOncoscience 22. July 2015
